Dwight Moxie - Revance Therapeutics, Chief Counsel
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
Executive
Dwight Moxie is Chief Counsel of Revance Therapeutics,
| Age | 48 |
| Phone | 615 724 7755 |
| Web | https://www.revance.com |
Dwight Moxie Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dwight Moxie against Revance Therapeutics, stock is an integral part of due diligence when investing in Revance Therapeutics,. Dwight Moxie insider activity provides valuable insight into whether Revance Therapeutics, is net buyers or sellers over its current business cycle. Note, Revance Therapeutics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Revance Therapeutics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dwight Moxie over six months ago Disposition of 23853 shares by Dwight Moxie of Revance at 17.8141 subject to Rule 16b-3 |
Revance Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.2436) % which means that it has lost $0.2436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance Therapeutics,'s management efficiency ratios could be used to measure how well Revance Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.Revance Therapeutics, currently holds 478.43 M in liabilities with Debt to Equity (D/E) ratio of 2.94, implying the company greatly relies on financing operations through barrowing. Revance Therapeutics, has a current ratio of 3.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Revance Therapeutics,'s use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Shiva CPA | 89bio Inc | 59 | |
| Christina MBA | Blueprint Medicines Corp | 49 | |
| David JD | Akero Therapeutics | N/A | |
| David MD | Immunocore Holdings | 54 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Henry Pelish | Nuvalent | 52 | |
| Yun Bai | 89bio Inc | N/A | |
| Mike JD | Pliant Therapeutics | 52 | |
| Matthew MBA | Nuvalent | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Julie CCRP | DiaMedica Therapeutics | 50 | |
| Michael Baldwin | 89bio Inc | N/A | |
| Amanda Kurihara | 89bio Inc | N/A | |
| John Soglia | Nuvalent | N/A | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Kye MD | Ventyx Biosciences | N/A | |
| JD Esq | Terns Pharmaceuticals | 56 | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 |
Revance Therapeutics, Leadership Team
Elected by the shareholders, the Revance Therapeutics,'s board of directors comprises two types of representatives: Revance Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revance. The board's role is to monitor Revance Therapeutics,'s management team and ensure that shareholders' interests are well served. Revance Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revance Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dwight JD, Chief Counsel | ||
| Dustin Sjuts, Vice President of Strategy and Sales | ||
| Conor Gallagher, Head Aesthetics | ||
| Jeanie Herbert, Sr. Director of Investor Relations | ||
| Mark Foley, CEO Director | ||
| Erica Jordan, Chief Officer | ||
| Azita Nejad, VP Operations | ||
| Dwight Moxie, Chief Counsel | ||
| Justin Ford, VP People | ||
| Amie Krause, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Jessica Serra, Head ESG | ||
| Aubrey Rankin, Consultant | ||
| Tobin Schilke, CFO and Principal Financial Officer | ||
| Taryn Conway, Vice President of Marketing |
Revance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revance Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.54) % | |||
| Current Valuation | 680.39 M | |||
| Shares Outstanding | 104.39 M | |||
| Shares Owned By Insiders | 8.55 % | |||
| Shares Owned By Institutions | 87.45 % | |||
| Number Of Shares Shorted | 4.51 M | |||
| Price To Earning | (7.60) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |